trientine has been researched along with Anemia in 2 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " He was treated with trientine for more than 10 years and suffered from anemia and liver dysfunction." | 3.77 | Excess copper chelating therapy for Wilson disease induces anemia and liver dysfunction. ( Abe, S; Harada, M; Harada, R; Hiura, M; Honma, Y; Matsuhashi, T; Miyagawa, K; Shibata, M; Tabaru, A, 2011) |
| "Tetrathiomolybdate is a better choice than trientine for preserving neurologic function in patients who present with neurologic disease." | 2.72 | Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. ( Askari, F; Brewer, GJ; Carlson, M; Dick, RB; Fink, JK; Hedera, P; Kluin, KJ; Lorincz, MT; Moretti, P; Schilsky, M; Sitterly, J; Tankanow, R, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harada, M | 1 |
| Miyagawa, K | 1 |
| Honma, Y | 1 |
| Hiura, M | 1 |
| Shibata, M | 1 |
| Matsuhashi, T | 1 |
| Abe, S | 1 |
| Harada, R | 1 |
| Tabaru, A | 1 |
| Brewer, GJ | 1 |
| Askari, F | 1 |
| Lorincz, MT | 1 |
| Carlson, M | 1 |
| Schilsky, M | 1 |
| Kluin, KJ | 1 |
| Hedera, P | 1 |
| Moretti, P | 1 |
| Fink, JK | 1 |
| Tankanow, R | 1 |
| Dick, RB | 1 |
| Sitterly, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004339] | Phase 3 | 90 participants | Interventional | 1994-01-31 | Completed | ||
| Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease[NCT01472874] | 8 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
Alanine transaminase (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 50.89 |
Alanine transaminase (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 41.38 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 313.4 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 287.9 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 1.05 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 0.99 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 2214 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 1959 |
1 trial available for trientine and Anemia
1 other study available for trientine and Anemia
| Article | Year |
|---|---|
Excess copper chelating therapy for Wilson disease induces anemia and liver dysfunction.
Topics: Adult; Anemia; Ceruloplasmin; Chelating Agents; Chelation Therapy; Copper; Hemochromatosis; Hepatole | 2011 |